Skip to main content

Cutting Edge German Cannabis Possession Case Decided On Appeal

A Lübeck appeals court has exonerated a father and son of possession on the basis of “emergency” treatment. The case may help other German patients beat criminal charges

On the last day of May, a regional appeals court in Lübeck (in the north of Germany) published what might yet become a bellwether cannabis case. As a result, it will also be important to patients across the country for at least the next 18 months until recreational cannabis reform actually kicks in. Namely, the court found that both a father who sourced hundreds of grams for his seriously ill son and the son were innocent of violations of the German Narcotics Act.

In doing so, the court annulled a District Court ruling which held that the two defendants were guilty of six counts of possessing large amounts of narcotics. The pair faced large fines.

The regional court acquitted both men because the possession of cannabis was justified under German law as an “emergency.” Namely, the son suffers from painful spasticity, the amount prescribed for the same was not sufficient to properly treat the symptoms, and the father obtained cannabis for his son to fill the gap.

What makes this case stand out is that the son needed six to seven grams of cannabis a day to properly treat symptoms (which is on the higher end of reimbursement, to begin with). Beyond this, the court also recognized that health insurance companies are increasingly stringent with cannabis approvals, even when justified.

In this case, the court ruled that any criminal penalties otherwise justified are overridden by a critical and unfilled medical need.

A Terrible Predicament

While recreational cannabis reform is clearly moving in Germany, the reality is that it cannot move fast enough for those who are, like the defendant and his caregiver in this case, chronically ill but still not covered by public healthcare. Such patients are directly in the line of fire – which has not been averted yet – by a government that recognizes that recreational reform must happen soon and medical reform is now five years old.

It is bad enough that casual recreational users are still directly in the line of federal drug charges. But for a country where medical use is theoretically legal, there needs to be an amnesty issued soon to protect those who may yet be unfortunate enough to be charged.

This case, as a result, may well show up in the defense of literally hundreds if not thousands of patients whose cases are still pending before full reform becomes the law of the land.

Home Grow In Italy: Just Around The Corner?

The country is poised to follow a trend seen in multiple European countries – namely introducing recreational reform with a limited home grow option

Italy may join the European club of countries allowing home grow by the end of the year. A bill to allow home cultivation of up to four plants finally reached the Chamber of Deputies (the Italian version of the American House of Representatives) in late June.

If passed, the bill would allow not only home grow but would also allow judges to impose reduced sentences for those who still are considered in violation of the new law. It would also require judges to impose penalties on a case-by-case basis.

The point of the legislation is to reduce the amount of money flowing directly into the coffers of organized crime and rectify shortages in the country’s medical cannabis infrastructure, provision, and distribution system.

The bill is expected to be voted on in the coming weeks before being considered by the Italian Senate in early fall.

The Status of Cannabis Reform in Italy

Italy has largely followed other countries, namely Germany, into the cannabis legalization debate. The country began medical cultivation in earnest after Germany passed its own medical legalization bill in 2017 – with the oversight of the same performed by the military.

Beyond this, CBD or cannabis lite as it is referred to across Europe, has become extremely popular in the country. In addition, case law on home grow has gotten increasingly compelling. Despite the failure of a petition to legalize recreational cannabis at the Italian Supreme Court late last year, it is clear that the issue is moving forward anyway at the legislative level – probably also speeded along by continuing reform including on the home grow front in other European countries.

Home Grow – The European First Step Towards Full Legalization

Over the past few months, the idea of implementing home grow as a first step towards greater recreational reform has gone from anathema to popular on-ramp to full normalization.

Malta started the trend late last year. Luxembourg, whose government promised full recreational reform by 2024, subsequently followed suit this spring with a similar idea. Portugal is well on the way to doing the same. Germany, in all likelihood, will also implement some kind of home grow in the legalization discussion. This is because there is a similar problem with medical cannabis provision and compensation in Italy. Not enough patients are getting their prescriptions approved, forcing them into the black market – or home cultivation.

The Bleeding Edge Of International Cannabis Reform Is Being Forged By Women

Women are on the front lines of the war to legalize cannabis – and paying a heavy price

There are two high-profile cannabis cases right now that are making global headlines. Both of them involve women who have been caught with cannabis – and face years if not decades in prison.

In Russia, WNBA star Brittney Griner has just pled guilty to drug charges for bringing about a gram of liquid cannabis in her luggage as she embarked on what she thought would be a lucrative off-season abroad.

Just days before this, last week, an Israeli woman was sentenced to life imprisonment rather than the death sentence for drug possession (including cannabis) in the United Arab Emirates.

Women may not be represented equally in the industry at the executive level yet, but they are increasingly on the front end of the drug war as global laws change. Not to mention being subjected to heavy penalties.

Women Are “Half the Battle”

In North America, women are certainly more present in the industry than just about anywhere else – and from every level – from working in the industry itself to proudly identifying as consumers (which is, if one remembers just a few years ago, a real and welcome change.)

Indeed, it speaks volumes that a high-profile female American user would be targeted in Russia in what many observers are calling a bold power play to obtain an early release for Russians held in the US and for far worse “crimes.” Russian officials have even been quoted as saying that they have done nothing differently than some U.S. states still can (even though hemp is now federally legal).

Regardless, the entire scenario puts yet more of a spotlight on the political deadlock on federal legalization in the US – not to mention the state of reform in Russia.

Cannabis reform is also lagging throughout the Arab world. The UAE, like most Arabic countries, has not reformed its cannabis laws – much – although life in prison is preferable to the death penalty.

Regardless, this case too highlights the draconian penalties that still exist in some parts of the world for a plant with increasingly noted healing properties. Not to mention that such laws are being applied without regard to gender.

Will Boris Johnson’s Departure As Prime Minister Speed British Cannabis Reform?

The controversial politician was forced to announce his resignation last week. How will this affect the pace of British cannabis reform?

Through the lens of history, the passage of Boris Johnson through the country’s top political job may become forever associated, for good or for bad, with Brexit. How that plays out when it comes to forwarding cannabis reform in the now separated from EU regulations on the same is still unclear.

That said, on the CBD front, it appears that it’s full speed ahead. The Food Safety Authority (FSA) just announced that 12,000 CBD products are now legal for sale in the UK. This puts the country far ahead of the discussion in Europe, where Novel Food regulations have yet again put applications (and legalization) discussions on hold. However, one thing is also clear. The EU may have ruled that CBD is not a narcotic, but this change, along with any other decisions taken at this level, now has to be incorporated into national law in every EU country.

What Is Likely to Shake The Apple Cart?

Far more influential than anything the UK does right now is what is happening in Germany. The government has formally committed to recreational reform, formal hearings have been heard, a white paper will be issued and there is, more or less, a timetable of reform that is now being refined as necessary. The passage of recreational reform will also finally normalize the CBD conversation in Germany.

Beyond this, the normalization of cannabis in Europe’s largest economy – and the fourth largest in the world, will certainly move the needle not only in the EU but in the UK too.

From a medical standpoint, the issue has essentially stalled in the UK so far. That said, both Brexit and Covid – and now the tumult of British national politics – are not likely to be fertile ground for forward-thinking politics on this (or many other issues) until things become a bit less chaotic in the UK.

In the meantime, it is clear that limited cannabis reform is in the offing in special trials (see the mayor of London’s proposal on decrim).

For now, at least, as a result, “Global Britain” is following, not leading, on the cannabis discussion. And right now, all eyes are looking to the Bundestag, not Whitehall, to move the stakes if not the goalposts forward.

Researchers In Norway Explore Cannabis Treatments And Parkinson’s Disease

Parkinson’s disease is a condition that attacks the nervous system and involves the patient experiencing tremors, muscular rigidity, and slow, imprecise movements. The condition seems to mainly affect middle-aged and elderly people.

Scientific research has found that Parkinson’s disease can be caused by both genetic and environmental conditions, although there is still a great deal about the condition that is unknown.

It is estimated that as many as 10 million people suffer from Parkinson’s disease worldwide, with men being 1.5 times as likely to be diagnosed with the condition compared to women.

Researchers in Norway recently examined cannabis as a form of treatment for Parkinson’s disease, and the results provide hope. Below is more information about it via a NORML news release:

Bergen, Norway: Patients with Parkinson’s disease (PD) often report symptomatic benefits from the use of cannabis, according to survey data published in the journal Acta Neurologica Scandinavica.

Norwegian investigators surveyed cannabis use patterns and related attitudes among PD patients. Consistent with prior surveys, they reported that a significant minority of PD patients consume cannabis for symptom relief. Respondents were most likely to report improvements in motor function, sleep, and pain as a result of their marijuana use.

Observational trial data has determined that cannabis inhalation is associated with improvements in tremor, rigidity, pain, sleep, and bradykinesia (slowness of movement) in patients with PD. Placebo-controlled trial data has also determined that acute CBD administration (300mg) is associated with a statistically significant reduction in experimentally-induced anxiety and tremor in PD patients.

Full text of the study, “Cannabis use in Parkinson’s disease: A nationwide online survey,” appears inActa Neurologica ScandinavicaAdditional information on cannabis and PD is available from NORML.

Researchers In Brazil Find That CBD Is Ineffective For Restless Legs Syndrome

Restless leg syndrome may not sound like a serious condition, however, it can have a very negative impact on someone’s life that suffers from the condition. I know this firsthand, as I suffer from the condition.

The condition is characterized by ‘an unpleasant tickling or twitching sensation in the leg muscles when sitting or lying down, relieved only by moving the legs.’

It is estimated that as many as 10% of the global adult human population suffers from restless leg syndrome. It doesn’t seem to be known what ultimately causes the condition, although there are theories that it may be tied to fluctuating dopamine levels.

Whatever the cause, I can say from my own experience that restless leg syndrome is not only extremely annoying, it makes it nearly impossible to sleep at night. People that suffer from restless leg syndrome often also suffer from related insomnia.

Various treatments exist for restless leg syndrome, although there is no ‘one-size-fits-all’ treatment. What works for one person may not work for the next.

One form of treatment that I have followed closely is the use of CBD. I have had it recommended to me countless times, just to try it and not see any improvement. I wasn’t sure if it was just me, or if CBD was simply not an effective treatment.

Researchers in Brazil recently examined CBD and restless leg syndrome and found that it is an ineffective form of treatment. Below is more information about it via a news release from NORML:

Manaus, Brazil: The administration of oral doses of CBD is ineffective at reducing the severity of restless legs syndrome (RLS) in patients with Parkinson’s disease (PD) and REM sleep behavior disorder (RBD), according to clinical trial data published in the journal Cannabis and Cannabinoid Research.

Brazilian researchers compared the use of CBD versus a placebo over a 14-week period. Patients in the CBD arm of the trial received up to 300mgs of cannabidiol.

Patients who were administered CBD demonstrated no improvements compared to those receiving placebo.

“CBD showed no reduction in the severity of RLS manifestations in patients with PD and RBD,” authors concluded.

By contrast, a series of case reports published in 2020 and in 2017 reported that cannabis inhalation is associated with perceived efficacy in patients with refractory restless legs syndrome.

Full text of the study, “Cannabidiol for restless legs syndrome/Willis-Ekbom disease in Parkinson’s disease patients with REM sleep behavior disorder: A post hoc exploratory analysis of a phase 2/3 clinical trial,” appears in Cannabis and Cannabinoid Research.

Argentina’s Supreme Court Upholds Medical Cannabis Cultivation Rights

Medical cannabis advocates have tried for many years to get home cultivation officially approved in Argentina. Unfortunately, it has been a very slow process.

As we have mentioned in previous coverage, in 2017 lawmakers in Argentina passed a law that legalized cannabis for medical use. For the next few years, the new law essentially proved to be nothing more than symbolic as industry rules and regulations went nowhere.

In late 2020 Argentina’s President Alberto Fernández signed a decree calling for the legalization of home cultivation along with allowing pharmacies to sell medical cannabis products.

The catch to the 2020 decree, which is essentially the same catch that has hindered Argentina’s medical cannabis program since 2017, is that it relied on the creation of rules and regulations pertaining to licenses. Before someone can cultivate medical cannabis in Argentina they must first obtain a license from the government, and there essentially is no effective licensing process in place.

Medical cannabis advocates have pursued various legal remedies, and Argentina’s Supreme Court recently rendered a landmark decision that provides some legal protections for home cultivation. Per El Destape (auto-translated to English):

The Supreme Court of the Nation unanimously ratified the decriminalization of the use of cannabis for medicinal purposes and made it compulsory to register it in the official records for those who want to carry out this practice . The highest court ruled in this regard when evaluating the proposals of the Medicinal Cannabis Moms Association (Macame) of Santa Fe, which had questioned the constitutionality of the rules regarding the self-cultivation of cannabis for medicinal use by minors in their care.

“The public health and safety reasons involved are sufficient to justify the State issuing administrative authorizations within the framework of Law 27,350 for self-cultivation and the production of products derived from cannabis for medicinal purposes. This determines, in turn, that the intervention of the State in this area does not imply an unjustified interference in the personal autonomy of article 19 of the National Constitution”, he stressed.

Ultimately, what is needed is a fully functioning medical cannabis program in Argentina so that there is no room for doubt when it comes to the rights of medical cannabis patients.

Every patient should be able to cultivate cannabis legally based on codified laws that law enforcement is mandated to follow. Whenever patients have to rely on case law in the absence of codified law, it always creates situations that are ripe for selective enforcement which no patient should ever have to deal with.

Lawmaker Survey Finds Strong Support For Cannabis Reform In Guernsey

Guernsey is an island located within the English Channel off the coast of Normandy. It’s part of the Bailiwick of Guernsey, a British Crown Dependency. It’s likely not the first place that comes to mind when thinking about cannabis reform.

However, there is growing support for cannabis reform in Guernsey, including within lawmaker circles. The Guernsey Press recently analyzed survey answers involving lawmakers and their views about cannabis policy. Per the Guernsey Press:

Although some answers were nuanced or not particularly clear, we can work out that more than half of Guernsey deputies – Alderney representatives in the States were not involved – were supportive of the medicinal use of cannabis.

More than half were again supportive towards looking again at the way cannabis is regulated.

And about 40% were open to some form of legalisation of the Class B drug for personal use.

It’s always a nuanced thing when lawmakers express general support for cannabis reform, in that their support is just that – general. It doesn’t provide insight into what specific provisions they may support.

Do they support home cultivation? Do they support a regulated industry? There are a number of policy components that go into cannabis policy reform, and any number of them could result in a lawmaker switching from ‘supportive’ to ‘opposed.’

Still, the survey results from Guernsey are encouraging. It could definitely be worse, with the numbers flip-flopped. Thankfully, that is not the case.

The German Cannabis Legalization Hearings

The several weeks-long hearing process has now come to an end. These are the takeaway high points

The hearings on the legalization of recreational cannabis are now a thing of the past. Announced in early June, they have now taken place and some clarity about the direction and timing of the German rec market is now emerging.

The first, most important takeaway is that Health Minister Karl Lauterbach and the Federal Drug Commissioner Burkhard Blienert (who will also keynote the International Cannabis Business Conference in Berlin in just a few weeks) have committed to making recreational cannabis a reality.

The importance of this commitment cannot be understated. Unlike US politics, the German federal government is more consensus-oriented. If two major leaders announce an initiative, chances are it will happen (although of course it does not always – see previous Health Minister Jens Spahn’s many pronouncements about the digitalization of healthcare). That said, Lauterbach also mentioned again that he had undergone a change in perspective about legalization unlike his counterparts in the Green and FDP parties – both of whom have been pro-legalization for quite some time now.

“The risks of the current situation are greater than the legal levy,” he said. “The coordinates have shifted in favour of legalization.” Blienart went a bit further than his boss. According to him, what is about to occur is a “paradigm shift” on the topic of cannabis.

For these reasons alone, the signs are here that what these two men have now pronounced will in fact occur.

The Timetable of Change

By autumn, according to Lauterbach, an overview paper discussing key points of the hearings (which were heard from 200 experts across a range of topics) will be released publicly. This in turn will lead to the drafting of the law to legalize recreational use. The actual debate and presumed passage of the bill have now been pushed back to the beginning of 2023. This means it is unlikely that an actual market will begin here before the beginning of 2024.

The intent, just like it was on the medical plunge, is to make this a four-year experiment that will be re-evaluated after the first period is over.

Other Key Takeaways

Industry sources have consistently spoken up about the need for a tax levy that allows legal cannabis to be price competitive with its black-market counterpart. There have been some discussions on how to manage the potency of product. One way that would not create regulatory but rather market control of price and potency would be to increase the price (and applicable tax) for products with a higher level of THC. This presumably also leaves the door open to a conversation beyond flower that moves quickly into both concentrates and edibles).

Beyond this, advertising is likely to be a part of the mix. A complete ban on the same will make it hard for the market to establish itself – and therefore is probably unlikely. This is especially true as German pharmacies, including cannabis specialty pharmacies, do not seem to want to be on the front lines of the rec experiment, unlike Switzerland.

Online sales are also likely to be verboten – at least at first.
Stay tuned. The results of the paper when published will have far more concrete suggestions as well as predict more accurately what will be both in (and out) of the now pending and absolutely historic law to make Germany, the world’s fourth-largest economy, a green and cannabis-friendly place.